Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189, a nectin-4 miniprotein radioconjugate

Kivu Bioscience announced HREC approval and Clinical Trial Notification (CTN) clearance in Australia to initiate...

Bispecific ADC Iza-bren meets both primary endpoints, significantly improving PFS and OS in unresectable or...

IDEAYA Biosciences announces first-patient-in for Phase 1 trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific...

Molecular partners signs development agreement with Eckert & Ziegler for targeted alpha radiotherapeutics

Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license